News | Stents Bifurcation | October 02, 2015

Tryton Side Branch Stent Clinical Trial Results Published

Analysis showed reductions in target vessel failure and improved side branch percent diameter stenosis in patients with a coronary bifurcation lesion in vessels 2.25mm in diameter or greater

Tryton Side Branch Stent, clinical trial results, Catheterization and Cardiovascular Interventions

Tryton Side Branch Stent image courtesy of Tryton Medical


October 2, 2015 — Tryton Medical Inc. announced that results of a post hoc analysis of the pivotal Tryton Randomized Clinical Trial (RCT) have been published in the peer-reviewed journal Catheterization and Cardiovascular Interventions (CCI). CCI is the official publication of the Society for Cardiovascular Angiography and Interventions (SCAI).

The analysis, “Outcomes of a dedicated stent in coronary bifurcations with large side branches: A subanalysis of the randomized TRYTON bifurcation study,” examines the use of the Tryton Side Branch Stent compared with provisional stenting in the intended treatment population of patients with a coronary bifurcation lesion in vessels 2.25mm in diameter or greater determined by quantitative coronary angiography (QCA).

The study authors — led by Martin B. Leon, M.D., director of the Center for Interventional Vascular Therapy at Columbia University Medical Center, New York-Presbyterian Hospital — conclude that treatment with the Tryton Side Branch Stent showed reductions in target vessel failure and improved side branch percent diameter stenosis in the population of patients with lesions involving side branches that were 2.25mm in diameter or greater. Both the Tryton Side Branch Stent and provisional treatment strategies were shown to have similarly low rates of stent thrombosis, and no cardiac deaths were reported at nine months.

“Coronary bifurcation lesions present a number of challenges for interventional cardiologists because each patient can present with varying vessel sizes and there is a wide range of angulations between the main vessel and side branch,” said Leon. “For the treatment of bifurcation lesions involving significant side branches, this analysis of the pivotal Tryton RCT provides strong support for the safety and efficacy of the Tryton Side Branch Stent compared with a provisional stenting strategy.”

In the post hoc analysis of 289 patients with a coronary bifurcation lesion involving a side branch greater than or equal to 2.25mm in diameter, target vessel failure (the primary endpoint) was numerically lower among the Tryton group compared to the provisional group. The device demonstrated a statistically significant lower side branch percent diameter stenosis at nine-month follow-up compared with the provisional group (30.4 percent vs. 40.6 percent, P = 0.004). In addition, the stent reduced the need for additional side branch “bail-out” stenting compared with the provisional approach (0.7 percent vs. 5.6 percent, P = 0.02). There was no significant difference in the rate of binary restenosis.

For more information: www.trytonmedical.com


Related Content

News | Stents Bifurcation

September 21, 2022 — Medtronic announced today that it has received Food and Drug Administration (FDA) approval for the ...

Home September 21, 2022
Home
News | Stents Bifurcation

May 29, 2018 – Medtronic plc announced the initiation of a U.S. clinical study to assess the safety and efficacy of drug ...

Home May 29, 2018
Home
News | Stents Bifurcation

January 18, 2018 – West Hills Hospital & Medical Center, a full-service acute care facility, announces the first ...

Home January 18, 2018
Home
Videos | Stents Bifurcation

Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at ...

Home November 15, 2017
Home
News | Stents Bifurcation

November 1, 2017 — The double kissing (DK) crush two-stent technique was associated with a lower rate of target lesion ...

Home November 01, 2017
Home
News | Stents Bifurcation

September 21, 2017 — Cardinal Health and Tryton Medical Inc. announced that the Tryton coronary Side Branch Stent was ...

Home September 21, 2017
Home
News | Stents Bifurcation

March 31, 2017 — Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch ...

Home March 31, 2017
Home
Videos | Stents Bifurcation

This video, provided by Tryton, demonstrates the implantation of the Tryton Side Branch Stent. It became the first ...

Home March 06, 2017
Home
Technology | Stents Bifurcation

March 6, 2017 – The U.S. Food and Drug Administration (FDA) has granted pre-market approval (PMA) for the Tryton Side ...

Home March 06, 2017
Home
News | Stents Bifurcation

October 28, 2016 – Tryton Medical Inc., a primary developer of stents to treat coronary bifurcation lesions, and ...

Home October 28, 2016
Home
Subscribe Now